GRANT OF OPTIONS AND DEALING BY PDMR

RNS Number : 2780B

Oncimmune Holdings PLC

03 April 2017

 

3 April 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

GRANT OF OPTIONS AND DEALING BY PDMR

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 31 March 2017, options over 175,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to certain US employees, including 20,000 to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:

Name	Position	Number of share options awarded	Option exercise price per share (pence)	Interest in issued share capital (%)
Dan Calvo	President of Oncimmune (USA) LLC	20,000	119	0.02

The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 30 March 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 119 pence, being the mid-market closing price of the Ordinary Shares on 31 March 2017

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dan Calvo
2	Reason for the notification
a)	Position/status	President of Oncimmune (USA) LLC, PDMR
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	options over Ordinary Shares - Oncimmune Holdings Plc Incentive Stock Option Plan   ISIN GB00BYQ94H38
b)	Nature of the transaction	Grant of options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) N/A 20,000
d)	Aggregated information	Price(s) Volume(s) N/A 20,000
e)	Date of the transaction	31 March 2017
f)	Place of the transaction	N/A

 

END

 

 

DSHDDGDSSGGBGRD